|
Omalizumab for the treatment of severe persistent allergic asthma |
Jones J, Shepherd J, Hartwell D, Harris P, Cooper K, Takeda A, Davidson P |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Jones J, Shepherd J, Hartwell D, Harris P, Cooper K, Takeda A, Davidson P. Omalizumab for the treatment of severe persistent allergic asthma. Health Technology Assessment 2009; 13(Suppl 2 Article 5): 31-39 Indexing Status Subject indexing assigned by NLM MeSH Anti-Asthmatic Agents /economics /therapeutic use; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Asthma /drug therapy; Cost-Benefit Analysiss; Omalizumab; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32013000708 Date abstract record published 10/10/2013 |
|
|
|